TY - JOUR
T1 - Neointimal hyperplasia of ultra-thin stents with microcrystalline sirolimus or durable polymer everolimus-eluting stents: 6- and 24-month results of the DESSOLVE III OCT study
AU - Milewski, Krzysztof
AU - Takahashi, Kuniaki
AU - Asano, Taku
AU - Katagiri, Yuki
AU - Hochul, Mariusz
AU - Buszman, Piotr P.
AU - Tomaniak, Mariusz
AU - Gorycki, Bogdan
AU - Zurakowski, Aleksander
AU - Janas, Adam
AU - Mlodziankowski, Adam
AU - Kachel, Mateusz
AU - Wykrzykowska, Joanna J.
AU - Wijns, William
AU - de Winter, Robbert J.
AU - Buszman, Pawel E.
AU - Onuma, Yoshinobu
AU - Serruys, Patrick W.
N1 - Publisher Copyright: © Europa Digital & Publishing 2021. All rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/2/19
Y1 - 2021/2/19
N2 - AIMS: The DESSOLVE III OCT substudy aimed to compare serially neointimal hyperplasia volume obstruction (%VO) between the thin-strut MiStent with early polymer elimination and nine-month sustained drug release from microcrystalline sirolimus and the durable polymer-coated everolimus-eluting XIENCE stent at six and 24 months after implantation. METHODS AND RESULTS: The efficacy endpoint was %VO, calculated as abluminal neointimal volume/stent volume. Thirty-six patients (MiStent 16 patients, 16 lesions; XIENCE 20 patients, 22 lesions) underwent serial OCT evaluation at both six and 24 months. At six months, mean abluminal %VO was significantly lower in the MiStent group than in the XIENCE group (14.54±3.70% vs 19.11±6.70%; p=0.011), whereas the difference in %VO between the two groups decreased at 24 months (20.88±5.72% vs 23.50±7.33%; p=0.24). There was no significant difference in percentage malapposed struts and percentage uncovered struts between the two groups at both time points. CONCLUSIONS: In the serial comparative OCT analysis of the MiStent versus the XIENCE, the MiStent showed a more favourable efficacy for preventing neointimal formation with comparable strut tissue coverage, as compared with the XIENCE at six months, but this difference in %VO decreased at 24 months so that the difference in neointima at 24 months was no longer significant.
AB - AIMS: The DESSOLVE III OCT substudy aimed to compare serially neointimal hyperplasia volume obstruction (%VO) between the thin-strut MiStent with early polymer elimination and nine-month sustained drug release from microcrystalline sirolimus and the durable polymer-coated everolimus-eluting XIENCE stent at six and 24 months after implantation. METHODS AND RESULTS: The efficacy endpoint was %VO, calculated as abluminal neointimal volume/stent volume. Thirty-six patients (MiStent 16 patients, 16 lesions; XIENCE 20 patients, 22 lesions) underwent serial OCT evaluation at both six and 24 months. At six months, mean abluminal %VO was significantly lower in the MiStent group than in the XIENCE group (14.54±3.70% vs 19.11±6.70%; p=0.011), whereas the difference in %VO between the two groups decreased at 24 months (20.88±5.72% vs 23.50±7.33%; p=0.24). There was no significant difference in percentage malapposed struts and percentage uncovered struts between the two groups at both time points. CONCLUSIONS: In the serial comparative OCT analysis of the MiStent versus the XIENCE, the MiStent showed a more favourable efficacy for preventing neointimal formation with comparable strut tissue coverage, as compared with the XIENCE at six months, but this difference in %VO decreased at 24 months so that the difference in neointima at 24 months was no longer significant.
KW - Drug-eluting stent
KW - Optical coherence tomography
KW - Quantitative coronary angiography
UR - http://www.scopus.com/inward/record.url?scp=85102216468&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85102216468&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31062697
U2 - https://doi.org/10.4244/EIJ-D-18-01201
DO - https://doi.org/10.4244/EIJ-D-18-01201
M3 - Article
C2 - 31062697
SN - 1774-024X
VL - 16
SP - 1187
EP - 1194
JO - EuroIntervention
JF - EuroIntervention
IS - 14
ER -